• Company to formulate exclusively for NuView Life Sciences VPAC1 molecular biomarker for prostate, breast cancer PET imaging clinical trials
Siemens’ PETNET Solutions Inc., a wholly owned subsidiary of Siemens Healthcare, will formulate the VPAC1 molecular biomarker 64Cu TP-3805 exclusively for clinical trials for the biopharmaceutical firm NuView Life Sciences, Inc., of Park City, Utah. Targeting the VPAC1 receptor over-expressed on the surface of malignant cancer cells, 64Cu TP-3805 is being studied for prostate and breast cancer imaging using positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MR). As a 64Cu-labeled peptide with a longer half-life (12.7 hours), 64Cu TP-3805 is better suited for clinical trial distribution across a large geographical area than other commonly used PET radiopharmaceuticals.
Contact for journalists
Jeff Bell
Siemens Healthcare
Phone: 610-448-6348; E-mail: jeffrey.t.bell@siemens.com
Follow us on Twitter: www.twitter.com/SiemensHealth
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide. Further information is available on the Internet at http://www.siemens.com.
NuView Life Sciences, Inc. (Park City, UT) is a biopharmaceutical company that has developed an innovative genomic compound for the molecular detection of a variety of cancers. The VPAC1 receptor, a member of the vasoactive intestinal peptide receptors (VIPRs), is over-expressed on the surface of malignant cells and is a major indicator for detection and angiogenesis of a number of types of cancers. Thomas Jefferson University and NuView developed a peptide that specifically binds to the VPAC1 receptor found on the surface of mutating cancer cells. The VPAC1 biomarker is a platform technology, for precision in-vivo cancer diagnosis, in-vitro cancer urine screening by identifying shed cancer cells in voided urine and may have application for precision cancer therapy delivery. For additional information about NuView Life Sciences, Inc., visit http://www.nuviewinfo.com.
